Current and emerging systemic treatment strategies for psoriasis. - Wikidata - awgldk - TriplyDB

Current and emerging systemic treatment strategies for psoriasis.

Current and emerging systemic treatment strategies for psoriasis.

http://www.wikidata.org/entity/Q38039491

about

Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.Anti-inflammatory effects of adenosine N1-oxide TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis.Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.ISG15: leading a double life as a secreted molecule.Current and potential immune therapies and vaccines in the management of psoriasis.Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.Real-World Experience With Apremilast in Treating Psoriasis.44-plex cytokine profile of cholesteatoma.Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.Targeting miR-21 to Treat Psoriasis

P2860

Q24626968-A1BBCB15-AD65-4C7C-BF15-472DA07417D9 Q34553191-3B5F2B29-F445-477A-AA0E-38FB9D16301F Q35021016-1501A733-6D38-4AA6-B147-003150D4FC7C Q35220914-F1201959-8540-4E7F-BE85-02A670C4D0A3 Q36740874-6EB84D0C-4F8F-494E-887C-D2094082BC55 Q36809721-7D3F29F4-0E6A-4E63-BC14-892FB64869F3 Q36977772-A82B8896-2FDE-46E5-85F7-8A906DDA0EF3 Q38723865-6F295A92-C409-4170-8691-74F0E71F937C Q39009439-E5CC8D48-AFF8-4943-94ED-00FD2CBB85E2 Q39311429-86055141-802A-4CFA-8590-FEE136206414 Q47862404-9AE66AA5-0535-43D2-92D6-193B29D65370 Q50091508-650DD145-C488-4CB2-946C-67D6F919DB0F Q57826324-61828B42-F7E9-4744-A3D8-751C55D9888D

P2860

Current and emerging systemic treatment strategies for psoriasis.

http://www.wikidata.org/entity/Q38039491

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current and emerging systemic treatment strategies for psoriasis.

@en

type

label

Current and emerging systemic treatment strategies for psoriasis.

@en

prefLabel

Current and emerging systemic treatment strategies for psoriasis.

@en

P1433

Q38039491-49C09656-7589-4C3D-923C-5BA9A70E7D11

P1476

Q38039491-44FE6FF1-EC07-460B-B015-6D9A1E803893

P2093

Q38039491-242FB691-3041-4216-9665-5BE082FA25E9

Q38039491-C88E0D13-AE0D-403F-BABF-8FD85BBABA7D

P2860

Q38039491-04740755-8E26-4DFC-BEC8-1128C869C8EF

Q38039491-05A8EB77-41C7-4A9C-9825-4F738BBEA78B

Q38039491-067B1652-A2F7-4622-A8AA-22456D8A5B62

Q38039491-0B723835-0F8A-457C-A786-E69AA62E4181

Q38039491-0CC54AD8-5246-4DBE-BBB6-B66D571B9E9A

Q38039491-0D399F16-21B7-43DA-BDAB-F91AD70D2A04

Q38039491-10D53463-397D-4654-99DF-DE7A309D40BE

Q38039491-1ABF170D-F0DC-442C-BE9F-F6C85AC9275F

Q38039491-2CF5AE9B-8A5C-4C67-8427-FBADD86E3844

Q38039491-31035BF4-3BCD-47F9-A2DC-C439B8D47D5F

P2888

Q38039491-C1762282-40FF-4510-89EB-1511977FC289

P304

Q38039491-208C9AA0-C5CB-4526-8B49-46BBA3FEDEA2

P31

Q38039491-0DF198C8-AA92-43D7-8B8A-DCB931043EB6

P356

Q38039491-7B843893-64D5-45D0-A975-589080D8E79A

P433

Q38039491-8DBCEF87-4AB5-4A44-9513-E174B15717C3

P478

Q38039491-7C305924-324A-4B67-89D1-789AE99C65D0

P577

Q38039491-CF80B47B-6FE7-4621-BED7-C1810D5F6B99

P6179

Q38039491-75BAFDF8-186C-4F11-99B4-7DFD2538F6E4

P698

Q38039491-CDE3CB40-7844-4A42-A939-48145BAC5DDB

P356

11634980-000000000-00000

P1433

P1476

Current and emerging systemic treatment strategies for psoriasis.

@en

P2093

Helen S Young

http://www.w3.org/2001/XMLSchema#string

Philip M Laws

http://www.w3.org/2001/XMLSchema#string

P2860

Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription

Therapeutic targeting of Janus kinases

Interleukin-17 and type 17 helper T cells

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.

Activation of protein kinase C isoforms and its impact on diabetic complications.

P2888

11634980-000000000-00000

P304

1867-1880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11634980-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030082253

http://www.w3.org/2001/XMLSchema#string

P698

22938141

http://www.w3.org/2001/XMLSchema#string